$ News

Evoke Pharma Reports Third Quarter 2025 Financial Results and Provides Business Update

UK Growth Companies With High Insider Ownership In November 2025

Evoke Pharma Enters into Definitive Agreement to Be Acquired by QOL Medical

UK Growth Stocks With Strong Insider Ownership

Evoke Pharma Announces Listing of New GIMOTI® Patent in FDA Orange Book

Evoke Pharma Second Quarter 2025 Earnings: Misses Expectations

Evoke Pharma, Inc. (NASDAQ:EVOK) Just Reported Earnings, And Analysts Cut Their Target Price

Evoke Pharma Reports Second Quarter 2025 Financial Results and Provides Business Update

Evoke Pharma Announces Issuance of New U.S. Patent for GIMOTI With Extended Exclusivity to Late 2038

Evoke Pharma Receives Notice of Allowance for U.S. Patent Application for GIMOTI Extending Orange Book listings to 2036

Breakeven On The Horizon For Evoke Pharma, Inc. (NASDAQ:EVOK)

Evoke Pharma Reports First Quarter 2025 Financial Results and Provides Business Update

Evoke Pharma to Present New Data Comparing Tardive Dyskinesia Incidence in Continuous vs Intermittent Metoclopramide Use at DDW 2025

Evoke Pharma, Inc. 2024 Q4 - Results - Earnings Call Presentation

Evoke Pharma, Inc. (NASDAQ:EVOK) Just Reported And Analysts Have Been Cutting Their Estimates

Q4 2024 Evoke Pharma Inc Earnings Call

Evoke Pharma Inc (EVOK) Q4 2024 Earnings Call Highlights: Revenue Surge and Strategic Growth Plans

Evoke Pharma, Inc. (EVOK) Q4 2024 Earnings Call Transcript

Evoke Pharma, Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Evoke Pharma to Report Fourth Quarter and Full Year 2024 Results on March 13, 2025